Enoxaparin is a frequently used anticoagulant in children. Unlike in adults, consensus guidelines recommend therapeutic monitoring to a target anti-factor Xa level of 0.5-1 U mL(-1) . Therapeutic ranges are not well correlated with clinical outcomes (e.g. thrombosis or hemorrhage), and assays are not standardized. Owing to limited reagent supplies, our clinical laboratory conducted a validation process and switched anti-FXa assays. Although the assays correlated well with each other, anti-FXa values were, on average, 33
作者：L A, Greene；C, Law；M, Jung；S, Walton；V, Ignjatovic；P, Monagle；L J, Raffini
来源：Journal of thrombosis and haemostasis : JTH 2014 年 12卷 9期
